30-Jan-2026
Bank of America Securities Keeps Their Sell Rating on Sarepta Therapeutics (SRPT)
TipRanks (Tue, 27-Jan 8:28 AM ET)
TipRanks (Tue, 27-Jan 7:20 AM ET)
TipRanks (Tue, 27-Jan 6:45 AM ET)
Business Wire (Mon, 26-Jan 8:00 AM ET)
Business Wire (Fri, 23-Jan 4:05 PM ET)
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Business Wire (Mon, 12-Jan 11:58 AM ET)
Business Wire (Wed, 7-Jan 8:30 AM ET)
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Business Wire (Mon, 5-Jan 8:30 AM ET)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 31-Dec 5:20 PM ET)
Business Wire (Thu, 11-Dec 7:00 AM ET)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of January 30, 2026, SRPT stock price declined to $20.34 with 1,897,626 million shares trading.
SRPT has a beta of 1.66, meaning it tends to be more sensitive to market movements. SRPT has a correlation of 0.06 to the broad based SPY ETF.
SRPT has a market cap of $2.13 billion. This is considered a Mid Cap stock.
Last quarter Sarepta Therapeutics reported $399 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $56 million and exceeded earnings estimates by $.33.
In the last 3 years, SRPT traded as high as $173.25 and as low as $10.42.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): IJR, XBI, FBT, VTI, VB.
SRPT has underperformed the market in the last year with a price return of -82.2% while the SPY ETF gained +15.6%. SRPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.5% and -3.7%, respectively, while the SPY returned +2.1% and 0.0%, respectively.
SRPT support price is $20.27 and resistance is $22.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT shares will trade within this expected range on the day.